Companies are going to have to adapt themselves to the concept of "Utilization assessment" of new developments in medical engineering. This applies not only to the products, but also to investigation and treatment methods. G-BA defines utilization here as a "more than a minor positive effect of a medical treatment on patients, when you consider the risk involved“.
Meaningful data about utilization, economy and medical requirements are gaining in importance. Health insurance would also like to have an evaluation of treatment methods after the market launch. Moreover, the manufacturers will have to increasingly provide comparative studies in the field of medical engineering, publish all the investigation results and fulfill demands for substantiation, if randomized study is not feasible.
[ilink url=“http://www.bvmed.de/presse/pressemitteilung/medinform-konferenz-zum-medtech-innovationszugang-nutzenbewertung-gewinnt-an-bedeutung.html“]Link to the source (BVMED)[/ilink]